MedTrace Logo

Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)

NCT00348153 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-12-03

No results posted yet for this study

Summary

TNF alpha Inhibitors have been very effective in treating rheumatologic diseases as well as uveitis. Adalimumab is the first member of a new class of TNF antibody compounds developed to contain exclusively human sequences. We want to test the efficacy and safety of the TNF alpha Inhibitor Adalimumab in patients with active uveitis despite standard immunosuppressive therapy.

Conditions

  • Uveitis

Interventions

DRUG

Adalimumab

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Hannes M Lorenz, MD · Department of Rheumatology, University of Heidelberg

  • Matthias D Becker, MD · Interdisziplinary Uveitis Center, University of Heidelberg

  • Regina Max, MD · Interdisziplinary Uveitis Center, University of Heidelberg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2012-09-30
Completion
2013-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00348153 on ClinicalTrials.gov